Testing the role of unstimulated in vitro maturation for potential development of immature oocytes in women with oocyte maturation abnormalities

Basit Öğe Kaydı
dc.authoridUrkmez, Sebati Sinan/0000-0002-8821-1835;
dc.contributor.authorKalyoncu, Senol
dc.contributor.authorBasbug, Alper
dc.contributor.authorHatirnaz, Ebru
dc.contributor.authorKaya, Aski Ellibes
dc.contributor.authorGungor, Nur Dokuzeylul
dc.contributor.authorUrkmez, Sebati Sinan
dc.contributor.authorUrkmez, Yesim Civil
dc.date.accessioned2025-10-11T20:47:39Z
dc.date.available2025-10-11T20:47:39Z
dc.date.issued2024
dc.departmentDüzce Üniversitesien_US
dc.description.abstractObjective: The aim of this study was to investigate the developmental potential of immature oocytes and evaluate whether unstimulated in vitro maturation (IVM) could serve as a treatment option for women with oocyte maturation abnormalities (OMAs). Material and Methods: This cohort study was conducted between September 2019 and December 2022, and included women who underwent unstimulated, non-human chorionic gonadotropin (hCG) priming IVM. Oocytes were incubated with IVM medium for 26-48 hours and evaluated to compare their maturation profiles with the immature oocytes retrieved from the same patients in their previous in vitro fertilization cycles. Results: Among the twelve women in the study, eleven (91.6%) underwent whole exome sequencing analysis. Of these, 18 variants were identified in 10 individuals, excluding case 1, who had no previous mutation analysis. Of the mutations identified, 9 (50%) were located in FSHR, 5 (27.8%) in TUBB8, 1 (5.6%) in ZP1, 1 (5.6%) in SLFN14, 1 (5.6%) in AR , and 1 (5.6%) in STEAP3. Apart from one woman with resistant ovary syndrome (ROS), none treated with unstimulated IVM had oocyte maturation. Remarkably, the only patient to achieve oocyte maturation in an unstimulated IVM cycle was case 11, who had ROS and a single FSHR variant. Conclusion: Unstimulated, non-hCG primed IVM does not appear to be effective in the treatment of OMAs, perhaps with the exception of women with ROS. However, this study led our team to develop novel treatment options based on physiological mechanisms for some subtypes and supraphysiological approach for other subtypes of OMAs. (J Turk Ger Gynecol Assoc. 2024; 25: 219-23)en_US
dc.identifier.doi10.4274/jtgga.galenos.2024.2023-10-9
dc.identifier.endpage223en_US
dc.identifier.issn1309-0399
dc.identifier.issn1309-0380
dc.identifier.issue4en_US
dc.identifier.pmid39069733en_US
dc.identifier.startpage219en_US
dc.identifier.trdizinid1309084en_US
dc.identifier.urihttps://doi.org/10.4274/jtgga.galenos.2024.2023-10-9
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1309084
dc.identifier.urihttps://hdl.handle.net/20.500.12684/21505
dc.identifier.volume25en_US
dc.identifier.wosWOS:001377184800001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofJournal of the Turkish-German Gynecological Associationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_WOS_20250911
dc.subjectOocyte maturation arresten_US
dc.subjectoocyte maturation abnormalitiesen_US
dc.subjectunstimulated in vitro maturationen_US
dc.subjectmutationen_US
dc.titleTesting the role of unstimulated in vitro maturation for potential development of immature oocytes in women with oocyte maturation abnormalitiesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu